Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 10/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 10/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.41 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | POLRMT | O00411 | 1/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368367 | 1.00 | PRMT5 (0.44) | PRMT5WDR77P2RY2P2RY1P2RY11 | |
| SCHEMBL16368075 | 0.89 | P2RY2 (0.40) | P2RY2P2RY1P2RY11P2RX1P2RX3 | |
| SCHEMBL31228172 | 0.88 | PRMT5 (0.45) | PRMT5WDR77P2RY2P2RY1P2RY11 | |
| SCHEMBL16368340 | 0.86 | P2RY1 (0.55) | P2RY2P2RY1P2RY11P2RX1P2RX3 | |
| SCHEMBL23171704 | 0.82 | POLG (0.49) | P2RY2P2RY4 | |
| SCHEMBL16368354 | 0.82 | POLG (0.49) | P2RY2P2RY4 | |
| SCHEMBL16647633 | 0.82 | POLG (0.49) | P2RY2P2RY4 | |
| SCHEMBL19986635 | 0.82 | PRMT5 (0.40) | PRMT5WDR77P2RY2P2RY1P2RY11 | |
| SCHEMBL21078486 | 0.80 | P2RY2 (0.42) | PRMT5WDR77P2RY2P2RY1P2RY11 | |
| SCHEMBL21006619 | 0.80 | P2RY2 (0.63) | PRMT5WDR77P2RY2P2RY1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3797782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Janssen BioPharma, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3160476-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION | JANSSEN BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| WO-2015054465-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | PRMT5 1351/4885WDR77 1808/4885P2RY2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.